Adding paclitaxel to standard chemotherapy for tough testicular cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests if adding a drug called paclitaxel to the standard chemotherapy combination (BEP) can improve outcomes for people with aggressive testicular cancer. It is for those whose tumor markers did not drop as fast as expected after the first round of chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have a type of testicular cancer called non-seminomatous germ cell tumor, or tumor markers strongly suggest it.
- The cancer is considered poor-prognosis, meaning it has spread to certain organs, is in the mediastinum (area between the lungs), or has very high tumor markers.
- You have not had chemotherapy before.
- You have no other active cancer that could affect your life expectancy (except minor skin cancers or early-stage cancers).
- Your kidneys, blood counts, and liver function meet minimum levels, and you have no HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a specific treatment approach works better for men with higher-risk non-seminomatous germ-cell tumors that have spread. Doctors will use tumor marker changes and where the cancer started (often the chest area) to help guide treatment choices.
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.
This Phase 3 trial tests two chemotherapy regimens (TC vs BEP) for women with malignant sex cord-stromal tumors of the ovary. It aims to see which treatment works better after you’ve had initial surgery to diagnose and/or remove tumor.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This study tests a treatment that combines chemotherapy given directly into the abdomen (intraperitoneal) with standard systemic chemotherapy for people whose gastrointestinal cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). It aims to control the cancer and improve how patients feel.
Hear when a new Germ Cell Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.